Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
KabaFusion, LLC, Cerritos, California, USA
Research Article
Intravenous versus Subcutaneous Immunoglobulin in Primary Immunodeficiency: Real-World Evaluation of Safety, Efficacy, and Patient Perceptions
Author(s): Bob Geng, Fawad Piracha, Nazia Rashid* and Michael Rigas
Background: Patients with primary immunodeficiency disorders (PIDD) typically require life-long immunoglobulin
(IG) replacement therapy. There are two routes of IG administration: intravenous (IVIG) and subcutaneous (SCIG).
To better understand routes of IG administration in the real-world, use in a home infusion setting was evaluated.
Objective: To evaluate the safety, efficacy, and perceived responses in PIDD patients on IVIG versus SCIG in a realworld,
home infusion setting.
Methods: Retrospective data were collected from 2010 to 2018 from a national home infusion pharmacy of PIDD
patients receiving IVIG or SCIG therapy for at least 6 months with evaluations for safety, efficacy, and patient
perception of response.
Results: A total of 149 patients were identified for analy.. View More»
DOI:
10.35248/2155-9899.20.11.589